2020 Activities Summary
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Questions & Answers on Influenza
101 Questions & Answers on Influenza101 101 Questions & Answers Prof. Dr. A.D.M.E. (Ab) Osterhaus is David De Pooter is working at Link Inc on professor of virology at Erasmus Medical since 2003, the Antwerp (Belgium) based Centre Rotterdam, and professor of communication consultancy agency, Environmental Virology at the Utrecht specialised in strategic communication University. Fascinated by the ingenious and social marketing. Link Inc is working ways viruses circumvent the immune with the European Scientific working Influenza system of their hosts to multiply and Group on Influenza (ESWI) since 1998 and spread, Osterhaus started his quest at the is taking care of the positioning of the interface of virology and immunology. He group, the strategy and the implementa Ab Osterhaus quickly translated new insights in this tion of the strategy by developing complex field to applications in animal and targeted communication tools. In this human vaccinology. In addition, he started capacity, David De Pooter is a professional David De Pooter his work on virus discovery, not only writer on medical topics and a communi focussing on the identification of a series cation manager of ESWI. As such he has of animal viruses, but also of new human established a fruitful and long standing viruses. collaboration with Prof Ab Osterhaus. (www.linkinc.be) 101 Questions & Answers on Influenza 101 101 Questions & Answers on Influenza Ab Osterhaus David De Pooter Elsevier, Maarssen © Elsevier, Maarssen 2009 Design: Studio Bassa, Culemborg Elsevier is an imprint of Reed Business bv, PO Box 1110, 3600 BC Maarssen, The Netherlands. To order: Elsevier Gezondheidszorg, Marketing dept., Antwoordnummer 2594 (freepost), 3600 VB Maarssen, The Netherlands. -
"Pandemieën Bij Mens En Dier: Zijn We Er Op Voorbereid?" Prof. Ab Osterhaus DVM
"Pandemieën bij mens en dier: zijn we er op voorbereid?" Prof. Ab Osterhaus DVM PhD Director Research Center for Emerging Infections and Zoonoses (RIZ) University of Veterinary Medicine Hannover, Germany MSD Webinar, januari 22 2021 Rinderpest 1745: The Netherlands 2003: Last case in Mauretania 2011: Eradicated 1980 1990 2000 2010 2020 Past decades: zoonoses at the origin of major human disease outbreaks pandemics Adapted from: Reperant LA, Cornaglia G, Osterhaus AD Curr Top Microbiol Immunol.2013 The importance of understanding the human-animal interface: from early hominins to global citizens Most recent outbreaks of avian influenza as reported to the OIE in the last 6 months. African swine fever African swine fever Crucial elements for pandemic preparedness to be established in ‘peacetime’ • Early warning systems • Pathogen discovery and characterization platforms • Diagnostic platforms • Mathematical models • Animal models in BSL3 facilities • Clinical trial platforms • Non-pharmaceutical intervention and treatment strategies • Pharmaceutical intervention strategies •antiviral platforms •vaccine platforms •BRM platforms • Communication 8 25.01.2021 Last four influenza pandemics Credit: US National Museum of Health and Medicine 1918 1957 1968 2009 “Spanish Flu” “Asian Flu” “Hong Kong Flu” “Mexican flu” >40 million deaths 1-4 million deaths 1-4million deaths 0.2-0.6 million deaths A(H1N1) A(H2N2) A(H3N2) A(H1N1) Within a few weeks, the 2009 H1N1 pandemic spread around the world affecting all countries April 2009 May 2009 START June 2009 March 2009 July 6 2009 Cumulative cases 1–10 11–50 51–500 500–5000 Air traffic from Mexico >5000 De Jong et al., Nature 1997 Claas & Osterhaus, Nat.Med 1998 Fouchier et al., J Virol., 2005 Munster et al., EID., 2005 Aquatic wild birds Olsen et al., Science., 2006 Influenza A virus reservoir BF Koel et al, Science. -
Taking Organs-On-A-Chip to the Next Level
#1 Volume 11 October 2020 Medicines is the news magazine of Figon Regenerative pharmacology Taking organs-on-a-chip to the next level In this issue Clémence Ross-van Dorp Towards humans-on-a-chip The FIGON Dutch Medicines Days This former Dutch State Secretary, and Regenerative pharmacology allows an (DMD) are held online this year, throughout keynote speaker at the DMD, was entirely new perspective on human the fall of 2020. Check out the webinars at appointed Ambassador for the Dutch life physiology, health and disease. ‘These figondmd.nl. Keynote speakers are sciences and health sector. She is new methods are more closely related to presenting their topics in this issue. strengthening national networks. the intact human body.’ XXPage 10-27 XXPage 10 XXPage 20 Register via single-use.nu/ event/register Single-Use Event 2020 CORPUS | Leiden | November 10 On November 10th at location CORPUS in Leiden suppliers and users will meet at the ultimate networking event in the world of bioprocessing, biotechnology and (bio)pharmaceutical manufacturing. You are welcome to view and test new products, network with key suppliers in the single-use industry, and attend presentations about the latest developments in single-use. Editorial It takes an entire team he battle against COVID-19 is like the Olympics: a gargantuan international ef- fort with high personal, economic and emotional stakes. In fact, since the Olym- Tpics were cancelled this year, COVID-19 seems to have taken their place. It keeps us addicted to our news sour- ces. It is the talk of the day. And it brings together science, policy, business and societal organisations. -
Strategies for Improving Influenza Immunization Rates Among Hard-To-Reach Populations
Journal of Urban Health: Bulletin of the New York Academy of Medicine, Vol. 84, No. 4 doi:10.1007/s11524-007-9197-z * 2007 The New York Academy of Medicine For permissions, please e-mail: [email protected] Advance Access publication Strategies for Improving Influenza Immunization Rates among Hard-to-Reach Populations David Vlahov, Micaela H. Coady, Danielle C. Ompad, and Sandro Galea ABSTRACT Whereas considerable attention has been devoted to achieving high levels of influenza immunization, the importance of this issue is magnified by concern over pandemic influenza. Most recommendations for vaccine administration address high risk groups such as the elderly and those with chronic diseases, but coverage for hard- to-reach (HTR) populations has had less attention. HTR populations include minorities but also include other primarily urban groups such as undocumented immigrants, substance users, the homeless, and homebound elderly. Obstacles to the provision of immunization to HTR populations are present at the patient, provider, and structural levels. Strategies at the individual level for increasing immunization coverage include community-based educational campaigns to improve attitudes and increase motivation for receiving vaccine; at the provider level, education of providers to encourage immunizations, improving patient–provider interactions, broadening the provider base to include additional nurses and pharmacists, and adoption of standing orders for immunization administration; and at the structural level, promoting -
OPTIONS X Programme
Options X for the Control of Influenza | WELCOME MESSAGES BREAKTHROUGH INFLUENZA VACCINES TAKE LARGE DOSES OF INNOVATION Protecting people from the ever-changing threat of influenza takes unwavering commitment. That’s why we’re dedicated to developing advanced technologies and vaccines that can fight influenza as it evolves. We’re with you. ON THE FRONT LINETM BREAKTHROUGH INFLUENZA VACCINES TAKE LARGE DOSES OF INNOVATION CONTENT OPTIONS X SUPPORTERS ------------------- 4 OPTIONS X EXHIBITORS & COMMITTEES ------------------- 5 AWARD INFORMATION ------------------- 6 WELCOME MESSAGES ------------------- 7 SCHEDULE AT A GLANCE ------------------- 10 CONFERENCE INFORMATION ------------------- 11 SOCIAL PROGRAMME ------------------- 14 ABOUT SINGAPORE ------------------- 15 SUNTEC FLOORPLAN ------------------- 16 SCIENTIFIC COMMUNICATIONS ------------------- 17 PROGRAMME ------------------- 19 SPEAKERS ------------------- 31 SPONSORED SYMPOSIA ------------------- 39 ORAL PRESENTATION LISTINGS ------------------- 42 POSTER PRESENTATION LISTINGS ------------------- 51 ABSTRACTS POSTER DISPLAY LISTINGS ------------------- 54 SPONSOR AND EXHIBITOR LISTINGS ------------------- 80 EXHIBITION FLOORPLAN ------------------- 83 Protecting people from the ever-changing threat of NOTE ------------------- 84 influenza takes unwavering commitment. That’s why we’re dedicated to developing advanced technologies and vaccines that can fight influenza as it evolves. We’re with you. ON THE FRONT LINETM Options X for the Control of Influenza | OPTIONS X SUPPORTERS -
Curriculum Vitae Ralph S. Baric
Curriculum Vitae Ralph S. Baric I. CONTACT INFORMATION: Department of Epidemiology School of Public Health University of North Carolina at Chapel Hill 2105-D McGaveran-Greenberg Hall, CB# 7400 Chapel Hill, North Carolina 27599-7400 Phone: 919-966-3895 II. EDUCATION: A. North Carolina State University, Raleigh, North Carolina, B.S., Zoology, 1977 B. North Carolina State University, Raleigh, North Carolina, Ph.D., Microbiology, 1983 C. University of Southern California, School of Medicine, Department of Microbiology and Neurology, Post-doctoral Fellow, 1982-1986 III. PROFESSIONAL EXPERIENCE: A. Assistant Professor, Department of Parasitology and Laboratory Practice, University of North Carolina at Chapel Hill, March 1986-June 1990 B. Assistant Professor, Department of Epidemiology, University of North Carolina at Chapel Hill, July 1990-June 1993. C. Associate Professor, Department of Epidemiology, University of North Carolina at Chapel Hill, July 1993-2001. D. Associate Professor, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, July 1993-2001 E. Professor, Department of Epidemiology, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, July 2002-current IV. HONORS AND AWARDS: A. Full Athletic Scholarship, Swimming, North Carolina State University, 1973-1976 B. Atlantic Coast Conference Champion and record holder: 500 yard Freestyle, 1000 yard Freestyle, 1650 yard Freestyle, 400 yard Individual Medley, 800 yard Freestyle Relay C. Teaching Assistantship, North Carolina State University, 1977-1978 D. Agricultural Foundation Pre-doctoral Research Assistantship, 1978-1981 E. Teaching Assistantship, North Carolina State University, 1981-1982 F. NIH Postdoctoral Fellowship, Neurology Training Grant, 1982-1984 G. Harvey Weaver Scholar, National Multiple Sclerosis Society Fellowship, 1984-86 H. -
Corman-Drosten Review Report
Healthy Gallatin From: Owen Giddings <[email protected]> Sent: Wednesday, February 3, 2021 3:30 PM To: BOHPublicComment Subject: Vaccination rates Categories: NonAgendaPC Could the Health Board please speak in concrete terms to why Gallatin County is lagging significantly behind all of Montana's other large cities in vaccination rates, per the Montana Covid dashboard? First shots administered: as of 2/3: Missoula Count (Missoula): 12.9% vaccinated Lewis and Clark County (Helena): 14.4% vaccinated Yellowstone County (Billings): 14.6% vaccinated Cascade County (Great falls): 12.8% vaccinated Gallatin County: 8.1% vaccinated Silver Bow County (Butte): 17.7% vaccinated 1 Healthy Gallatin From: Administrator <[email protected]> Sent: Wednesday, February 3, 2021 1:29 PM To: BOHPublicComment Subject: mask mandate Categories: NonAgendaPC BOH members and staff, I continue to be dismayed at the lack of enforcement of the mask order in commercial establishment in Bozeman. The BOH inclusion of an exemption for medical reasons provides an illogical loophole big enough for the Queen Mary. Nobody with an actual respiratory health issue is going to be maskless out in public and run the risk of encountering some asymptomatic anti‐masker. Responsible businesses include an option for curbside service for those who don’t want to comply with the mask requirement. The choice to enter a business includes the responsibility to adhere to the safety policies of that business. Smoking or going naked are not tolerated by businesses, going maskless shouldn’t be either. Employees maybe exposed to scores or hundreds of customers each day. Gallatin County’s positivity rate all but insures that the typical service industry employee will encounter people who are infected. -
V21 MTG 0033 List of Particip
THE FIRST WHO INTEGRATED MEETING ON DEVELOPMENT AND CLINICAL TRIALS OF INFLUENZA VACCINES THAT INDUCE BROADLY PROTECTIVE AND LONG-LASTING IMMUNE RESPONSES Baptist University, Hong Kong 24 – 26 January 2013 LIST OF PARTICIPANTS Dr Akira Ainai, Emeritus Member, National Institute of Infectious Diseases, Tokyo, Japan Dr Christopher Ambrose, Senior Director, Medical Affairs, MedImmune, Gaithersburg, United States of America Professor Filippo Ansaldi, Health Sciences, University of Genoa and Hygiene Unit, Genoa, Italy Dr Robert L. Atmar, Associate Professor, Department of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, United States of America Dr Emma Ball, CSL Limited A.C.N., Parkville, Victoria, Australia Dr Pamuk Bilsel, FluGen Inc., Madison, United States of America Mr Albert Chan, President, Hong Kong Baptist University, Hong Kong, China Dr Paul Chan, Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China Dr Marta Coehlo Nunes, Respiratory and Meningeal Pathogens Research Unit, Wits University, Johannesburg, South Africa Dr Ben Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China Dr Manon Cox, President and CEO, Protein Sciences Corporation, Meridien, United States of America Professor Rebecca Cox, Influenza Centre, The Gade Institute, University of Bergen, Bergen, 5021 Norway Dr Giuseppe Del Giudice, Global Head Translation Medicine, Novartis Vaccines and Diagnostics S.p.A, Divisione Biologici -
Drosten Review Report
HOME MAIN REVIEW REPORT CORMAN- RETRACTION REQUEST LETTER SUBMISSION DROSTEN CONSORTIUM FALSE-POSITIVES CONSEQUENCES REVIEW DOWNLOADS CONFERENCES OUTREACH MIRRORS REPORT CONTACT & IMPRINT CURATED BY AN INTERNATIONAL CONSORTIUM OF SCIENTISTS IN LIFE SCIENCES (ICSLS) Review report Corman-Drosten et al. Eurosurveillance 2020 November 27, 2020 TThhiiss eexxtteennssiivvee rreevviieeww rreeppoorrtt hhaass bbeeeenn ooffffiicciiaallllyy ssuubbmmiitttteedd ttoo EEuurroossuurrvveeiillllaannccee eeddiittoorriiaall bbooaarrdd oonn 2277tthh NNoovveemmbbeerr 22002200 vviiaa tthheeiirr ssuubbmmiissssiioonn--ppoorrttaall,, eenncclloosseedd ttoo tthhiiss rreevviieeww rreeppoorrtt iiss aa rr ee tt rr aa cc tt i i oo nn rr ee qq uu ee ss tt l l ee tt tt ee rr ,, ssiiggnneedd bbyy aallll tthhee mmaaiinn && ccoo--aauutthhoorrss.. FFiirrsstt aanndd llaasstt lliisstteedd nnaammeess aarree tthhee ffiirrsstt aanndd sseeccoonndd mmaaiinn aauutthhoorrss.. AAllll nnaammeess iinn bbeettwweeeenn aarree ccoo--aauutthhoorrss.. EE xx tt ee rr nn aa ll pp ee ee rr rr ee vv ii ee ww oo ff tt hh ee RR TT PP CC RR tt ee ss tt tt oo dd ee tt ee cc tt SS AA RR SS -- CC oo VV -- 22 rr ee vv ee aa ll ss 11 00 mmaa jj oo rr ss cc ii ee nn tt ii ff ii cc ff ll aa ww ss aa tt tt hh ee mmoo ll ee cc uu ll aa rr aa nn dd mmee tt hh oo dd oo ll oo gg ii cc aa ll ll ee vv ee ll :: cc oo nn ss ee qq uu ee nn cc ee ss ff oo rr ff aa ll ss ee pp oo ss ii tt ii vv ee rr ee ss uu ll tt ss . -
Better Global Tools for Influenza
11–12 June 2019 | Geneva, Switzerland BETTER GLOBAL TOOLS FOR INFLUENZA Technical consultation on product research & innovation for influenza prevention, control & treatment Prevent. Control. Prepare. 11–12 June 2019 | Geneva, Switzerland BETTER GLOBAL TOOLS FOR INFLUENZA Technical consultation on product research & innovation for influenza prevention, control & treatment WHO/WHE/IHM/IPR/2019.1 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Better global tools for influenza. Technical consultation on product research and innovation for influenza prevention, control and treatment, Geneva, Switzerland, 11-12 June 2019. -
MERS-Cov) in Humans November 12, 2013 · Research Article - the WHO MERS-Cov Research Group the WHO MERS-Cov Research Group
State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans November 12, 2013 · Research Article - The WHO MERS-CoV Research Group The WHO MERS-CoV Research Group -. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans. PLOS Currents Outbreaks. 2013 Nov 12 . Edition 1. doi: 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8. Abstract BACKGROUND: Between September 2012 and 22 October 2013, 144 laboratory-confirmed and 17 probable MERS-CoV cases from nine countries were notified to WHO. METHODS: We summarize what is known about the epidemiology, virology, phylogeny and emergence of MERS-CoV to inform public health policies. RESULTS: The median age of patients (n=161) was 50 years (range 14 months to 94 years), 64.5% were male and 63.4% experienced severe respiratory disease. 76.0% of patients were reported to have ?1 underlying medical condition and fatal cases, compared to recovered or asymptomatic cases were more likely to have an underlying condition (86.8% vs. 42.4%, p<0.001). Analysis of genetic sequence data suggests multiple independent introductions into human populations and modelled estimates using epidemiologic and genetic data suggest R<sub>0</sub> is <1, though the upper range of estimates may exceed 1. Index/sporadic cases (cases with no epidemiologic-link to other cases) were more likely to be older (median 59.0 years vs. 43.0 years, p<0.001) compared to secondary cases, although these proportions have declined over time. 80.9% vs. 67.2% of index/sporadic and secondary cases, respectively, reported ?1 underlying condition. -
Evidence of the Use of the Pandemic to Reduce the Population of The
1 BIOTERRORISM EVIDENCE Evidence that an international corporate criminal syndicate, which has annexed high government office inside the United States, is intent on carrying out a mass genocide against the people of the United States by using an artificial (genetic) flu pandemic virus and a forced vaccination program to cause mass death and injury and depopulate America in order to transfer control of the United States to WHO, the UN and affiliated security forces (UN troops from countries such as China, Canada, the UK and Mexico etc). 2 Contents I. Introduction: Summary of Claims II. Factual Background III. Evidence the “swine flu“ vaccines meets the criteria for definition as “bioweapons” IV. Scientific evidence the “swine flu” virus is an artificial (genetically engineered) virus V. Scientific evidence the “swine flu” was bioengineered to resemble the Spanish flu killer virus of 1918 VI. Genome sequence of the “swine flu” VII. Evidence as to the role of Baxter and WHO in producing and releasing 72 kilos of lethal pandemic virus material in Austria, nearly triggering a pandemic this winter VIII. Evidence Baxter is an element in a covert bioweapons network: Baxter officers IX. Evidence Baxter has deliberately contaminated drugs X. Evidence Novartis is using vaccines as bioweapons. XI. Evidence as to the WHO’s role in the bioweapons program: supplier of the bird flu virus to Baxter XII. Evidence as to deliberate release of the “swine flu” virus in Mexico XIII. Evidence as to the involvement of President Obama XIV. Evidence as to WHO’s manipulation of disease data in order to justify declaring a Pandemic Level 6 in order to seize control of the USA XV.